Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTC:AAWH NASDAQ:KROS NASDAQ:PVLA NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.73+6.6%$0.51$0.26▼$1.02$148.22M1.17166,627 shs88,533 shsKROSKeros Therapeutics$15.59+0.3%$14.39$9.12▼$72.37$633.19M1.06472,423 shs537,578 shsPVLAPalvella Therapeutics$55.68+2.8%$39.37$11.17▼$58.22$615.82M-0.03124,112 shs173,449 shsRZLTRezolute$8.00+8.4%$6.03$2.21▼$8.06$695.97M0.03738,004 shs1.56 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness+6.62%-13.69%+54.29%+126.56%-21.20%KROSKeros Therapeutics+0.26%+2.50%+8.19%+3.66%-70.55%PVLAPalvella Therapeutics+2.84%+2.83%+42.51%+119.21%+5,567,999,900.00%RZLTRezolute+8.40%+12.36%+40.60%+80.59%+70.21%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAAWHAscend Wellness$0.73+6.6%$0.51$0.26▼$1.02$148.22M1.17166,627 shs88,533 shsKROSKeros Therapeutics$15.59+0.3%$14.39$9.12▼$72.37$633.19M1.06472,423 shs537,578 shsPVLAPalvella Therapeutics$55.68+2.8%$39.37$11.17▼$58.22$615.82M-0.03124,112 shs173,449 shsRZLTRezolute$8.00+8.4%$6.03$2.21▼$8.06$695.97M0.03738,004 shs1.56 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAAWHAscend Wellness+6.62%-13.69%+54.29%+126.56%-21.20%KROSKeros Therapeutics+0.26%+2.50%+8.19%+3.66%-70.55%PVLAPalvella Therapeutics+2.84%+2.83%+42.51%+119.21%+5,567,999,900.00%RZLTRezolute+8.40%+12.36%+40.60%+80.59%+70.21%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAAWHAscend Wellness 1.00SellN/AN/AKROSKeros Therapeutics 2.50Moderate Buy$30.0092.43% UpsidePVLAPalvella Therapeutics 3.09Buy$58.505.06% UpsideRZLTRezolute 3.17Buy$12.5056.25% UpsideCurrent Analyst Ratings BreakdownLatest AAWH, KROS, RZLT, and PVLA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/19/2025PVLAPalvella TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $66.008/15/2025PVLAPalvella TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$38.00 ➝ $75.008/15/2025PVLAPalvella TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$50.00 ➝ $60.008/12/2025AAWHAscend WellnessZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell8/8/2025KROSKeros TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $20.008/5/2025PVLAPalvella TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$54.008/4/2025PVLAPalvella TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$90.007/21/2025PVLAPalvella TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$56.006/10/2025KROSKeros TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$32.00 ➝ $18.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAAWHAscend Wellness$518.59M0.29$0.11 per share6.64$0.69 per share1.05KROSKeros Therapeutics$3.55M178.38N/AN/A$14.11 per share1.10PVLAPalvella Therapeutics$42.81M14.38N/AN/A$5.58 per share9.98RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAAWHAscend Wellness-$48.21M-$0.42N/AN/AN/A-15.47%-72.18%-9.55%N/AKROSKeros Therapeutics-$187.35M$0.3150.29N/A2.018.06%2.96%2.74%11/5/2025 (Estimated)PVLAPalvella Therapeutics-$17.43M-$12.10N/AN/AN/AN/A-62.30%-43.34%11/12/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)Latest AAWH, KROS, RZLT, and PVLA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/18/2025Q4 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A8/14/2025Q2 2025PVLAPalvella Therapeutics-$0.78-$0.86-$0.08-$0.86N/AN/A8/6/2025Q2 2025KROSKeros Therapeutics-$1.14-$0.76+$0.38-$0.76$3.83 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAAWHAscend WellnessN/AN/AN/AN/AN/AKROSKeros TherapeuticsN/AN/AN/AN/AN/APVLAPalvella TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAAWHAscend Wellness2.611.470.80KROSKeros TherapeuticsN/A21.1121.11PVLAPalvella TherapeuticsN/A7.677.67RZLTRezoluteN/A8.438.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAAWHAscend Wellness17.31%KROSKeros Therapeutics71.56%PVLAPalvella Therapeutics40.11%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipAAWHAscend Wellness22.38%KROSKeros Therapeutics20.60%PVLAPalvella Therapeutics20.50%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAAWHAscend Wellness2,300204.44 million166.44 millionNot OptionableKROSKeros Therapeutics10040.62 million32.25 millionOptionablePVLAPalvella TherapeuticsN/A11.06 million8.79 millionN/ARZLTRezolute4087.00 million71.00 millionOptionableAAWH, KROS, RZLT, and PVLA HeadlinesRecent News About These CompaniesRezolute, Inc. $RZLT Shares Bought by OMERS ADMINISTRATION CorpSeptember 6 at 4:43 AM | marketbeat.comRezolute (NASDAQ:RZLT) Earns "Buy" Rating from HC WainwrightSeptember 6 at 2:59 AM | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5 at 10:20 AM | marketbeat.comRezolute (NASDAQ:RZLT) Receives "Buy" Rating from HC WainwrightSeptember 5 at 8:25 AM | marketbeat.comADAR1 Capital Management LLC Cuts Stock Position in Rezolute, Inc. $RZLTSeptember 4 at 7:42 AM | marketbeat.comNantahala Capital Management LLC Sells 1,566,587 Shares of Rezolute, Inc. $RZLTSeptember 3 at 7:08 AM | marketbeat.comRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor HyperinsulinismSeptember 2, 2025 | globenewswire.comRezolute Aligns with FDA on Phase 3 Trial DesignSeptember 2, 2025 | tipranks.comVelan Capital Investment Management LP Reduces Stock Holdings in Rezolute, Inc. $RZLTAugust 31, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys 125,000 Shares of Rezolute, Inc. $RZLTAugust 28, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - Still a Buy?August 27, 2025 | marketbeat.comRezolute, Inc. to Present at Upcoming Investor Conferences in September 2025August 27, 2025 | quiverquant.comQRezolute to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comRezolute appoints Karnawat as Chief Commercial OfficerAugust 20, 2025 | msn.comRezolute Appoints New Chief Commercial OfficerAugust 20, 2025 | msn.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - What's Next?August 20, 2025 | marketbeat.comRezolute, Inc. Appoints Sunil Karnawat as Chief Commercial Officer to Advance Commercialization of ersodetugAugust 20, 2025 | quiverquant.comQRezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial OfficerAugust 20, 2025 | globenewswire.comAltium Capital Management LLC Has $881,000 Position in Rezolute, Inc. (NASDAQ:RZLT)August 14, 2025 | marketbeat.comVivo Capital LLC Sells 685,272 Shares of Rezolute, Inc. (NASDAQ:RZLT)August 9, 2025 | marketbeat.comRezolute to Participate in the BTIG Virtual Biotechnology ConferenceJuly 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAAWH, KROS, RZLT, and PVLA Company DescriptionsAscend Wellness OTC:AAWH$0.72 +0.05 (+6.62%) As of 09/5/2025 03:44 PM EasternAscend Wellness Holdings, Inc. engages in the cultivation, manufacture, and distribution of cannabis consumer packaged goods in the United States. The company offers flower, pre-rolls, concentrates, vapes, edibles, tinctures, and other cannabis-related products under the Common Goods, SimplyHerb, Ozone, Ozone Reserve, Royale, Tunnel Vision, Miss Grass, Lowell Smokes, Edie Parker, 1906, and AiroPro brands. It also owns, operates, and manages cannabis cultivation facilities and dispensaries. The company sells its products through company-owned retail stores and third-party licensed retail cannabis stores. Ascend Wellness Holdings, Inc. was incorporated in 2018 and is headquartered in New York, New York.Keros Therapeutics NASDAQ:KROS$15.59 +0.04 (+0.26%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$15.56 -0.03 (-0.16%) As of 09/5/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis. It also develops KER-012, which is in Phase II clinical trial to treat pulmonary arterial hypertension and cardiovascular disorders; and KER-065 that is in Phase I clinical trial for the treatment of obesity and neuromuscular diseases. In addition, the company has collaboration and license agreement with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize KER-050 and licensed products containing KER-050. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.Palvella Therapeutics NASDAQ:PVLA$55.68 +1.54 (+2.84%) As of 09/5/2025 04:00 PM EasternPalvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.Rezolute NASDAQ:RZLT$8.00 +0.62 (+8.40%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$8.03 +0.03 (+0.37%) As of 09/5/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
